Astellas Obtains FDA Approval For Lexiscan
This article was originally published in PharmAsia News
Astellas Pharma obtained U.S. FDA approval for Lexiscan injection, an A2A adenosine receptor agonist approved for use as a pharmacological stress agent in radionuclide myocardial perfusion imaging studies in patients unable to undergo adequate stress exercise testing. Astellas America Inc. obtained development and marketing rights of Lexiscan in North America from CV Therapeutics. Per the agreement between the firms, CV Therapeutics will now receive milestone payment of $12 million from Astellas. (Click here for more - Japanese language
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.